News | May 11, 2010

AAA Detection to Drive Stent-Graft Market to $1 Billion

May 12, 2010 - Increased detection and treatment of abdominal aortic aneurysms (AAAs) and peripheral arterial disease (PAD) will drive the U.S. peripheral vascular device market to over $5.3 billion by 2016, according to a new report by iData Research.

The U.S. peripheral vascular device market is worth $2.8 billion. The stent-graft and peripheral vascular stent segments will lead growth is in the market.

Nearly two million people have aortic aneurysms in the U.S., but only 20% of cases are detected. If left untreated, approximately one-third of AAAs will rupture, causing death in 75 to 90 percent of patients. Improved AAA screening will also lead to increased detection of thoracic aortic aneurysms (TAAs).

The report states that the market for peripheral stents, used for treating PAD, has seen strong double-digit growth since 2005, and is expected to grow much faster than the coronary stent market through 2016.

iData's global three-report series on the "Markets for Peripheral Vascular Devices 2010" covers stents, PTA balloon catheters, atherectomy devices, CTO devices, stent-grafts, surgical-grafts, AV access thrombectomy devices, inferior-vena-cava-filters, catheters, guidewires, introducer sheaths and VCDs.

For more information: www.idataresearch.net/idata/registration.php

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Biotronik, PRO-Kinetic Energy cobalt chromium coronary stent system, FDA approval
Technology | Stents Bare Metal| February 15, 2017
The PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from Biotronik has gained U.S. Food and Drug...
Biotronik Astron stent
Technology | Stents Peripheral| December 31, 2015
December 31, 2015 - The U.S.
Technology | Stents Bare Metal| December 09, 2015
Medinol U.S. recently opened their commercial business in Parsippany, New Jersey, followed by the launch of the...
News | Antiplatelet and Anticoagulation Therapies| June 11, 2015
Patients who received a bare metal coronary stent did not display significant differences in rates of adverse events...
Technology | July 22, 2014
July 22, 2014 — Boston Scientific announced it received U.S. Food and Drug Administration (FDA) approval for the Rebel...
Boston Scientific Rebel Platinum Chromium Coronary Stent System Bare Metal
News | March 13, 2014
Boston Scientific Corp. received CE marking for the Rebel Platinum Chromium Coronary Stent System, the company's latest...
Biosensors BioMatrix

The LEADERS Trial showed that the Biosensors BioMatrix, a drug-eluting stent with a biodegradable abluminal polymer coating, was functionally equivalent to a regular nonbiodegradable stent.

Feature | February 04, 2013 | Kamran Zamanian, Ph.D.
The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents,...
Overlay Init